Royalty Pharma (RPRX) Change in Acquisitions & Divestments (2019 - 2026)

Royalty Pharma has disclosed Change in Acquisitions & Divestments across 8 years of filings, most recently posting $4.3 million for Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments rose 50.0% year-over-year to $4.3 million; the TTM figure through Jun 2026 stood at $14.4 million (down 53.45% YoY), while the FY2025 annual figure was $21.2 million, up 7.28% from the prior year.
• Change in Acquisitions & Divestments came in at $4.3 million for Q2 2026 at Royalty Pharma, roughly flat from $4.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $274.6 million in Q1 2022 to a low of $1.4 million in Q1 2024.
• Average Change in Acquisitions & Divestments over 5 years is $57.8 million, with a median of $4.3 million recorded in 2026.
• Year-over-year, Change in Acquisitions & Divestments sank 94.1% in 2024 and soared 774.03% in 2025.
• Over 5 years, Change in Acquisitions & Divestments stood at $115.6 million in 2022, then slumped by 78.91% to $24.4 million in 2023, then plunged by 48.4% to $12.6 million in 2024, then sank by 77.12% to $2.9 million in 2025, then surged by 50.0% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $4.3 million in Q2 2026, $4.3 million in Q1 2026, and $2.9 million in Q4 2025.